Vical enters into agreement to manufacture HIV vaccine Print E-mail
By Staff and Wire Reports   
Thursday, 07 October 2010 07:56

Vical Incorporated (NASDAQ:VICL) announced today that it has received a contract of $2.4 million from IPPOX foundation to manufacture Plasmid DNA (pDNA) vaccines for the treatment of HIV.

Developed by EuroVacc program in 1998, a pDNA/Poxvirus boost program is currently in focus of the ‘Collaboration for AIDS Vaccine Discovery’s (CAVD)’ Poxvirus T-cell vaccine discovery consortium.  Multiple Phase-1 and 2 Clinical trials in Europe of the DNA/Poxvirus approach has been proven to be highly immunogenic.  Further clinical developments can be carried out in Africa if the results of human studies prove successful.

Vical Inc., based in San Diego, is a biopharmaceutical company which develops products based on its patented DNA delivery technology. The products have potential applications for the treatment of cancer or other life-threatening diseases. Under the CAVD program, the company will manufacture individual plasmids which will be combined and delivered as single vaccines. The company hopes to complete delivery by the fourth quarter of 2010.

Vical Inc. is a small-cap company with a market capitalization of $126.6 million. The trailing twelve months EPS (TTM) is $-0.58 and the average volume of trade has been 1.8 million. The 52 week high and low for the share was $4.17 and $2.19 respectively. The share is currently trading around $2.26.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus